MedTrace Logo

TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

NCT00077142 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2018-10-31

No results posted yet for this study

Summary

RATIONALE: TAC-101 may stop the growth of cancer by stopping blood flow to the tumor.

PURPOSE: This phase I/II trial is studying the side effects and best dose of TAC-101 and to see how well it works in treating patients with advanced hepatocellular carcinoma (liver cancer).

Conditions

Interventions

DRUG

TAC-101

Once daily by mouth on days 1-14, repeat every 21 days for 2 courses.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Taiho Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Melanie B. Thomas, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30
Primary Completion
2005-07-31
Completion
2005-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00077142 on ClinicalTrials.gov